" class="no-js "lang="en-US"> Eric Bend - Medtech Alert
Monday, September 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Eric Bend

Eric Bend

About Eric Bend

Dr. Bend joined PreventionGenetics in August 2018 as a Human Molecular Geneticist. His portfolio focuses on epilepsy and obesity. Dr. Bend received his Ph.D. in Neuroscience from the University of Utah, Salt Lake City. He then went on to complete a postdoctoral fellowship at University of Utah and a 2-year clinical molecular genetics fellowship at the Greenwood Genetic Center in South Carolina.

Related Story

Clinical Trials

 PreventionGenetics Receives FDA Approval for its Companion Diagnostic Genetic Test as a Class II Medical Device | Pharmtech Focus

PreventionGenetics Receives FDA Approval for its Companion Diagnostic Genetic Test as a Class II Medical Device

July 1 2022

PreventionGenetics, a subsidiary of Exact Sciences Corp., announced today that it was recently granted marketing […]